Transgenic mammals expressing mutant gp iiia
CA 2325817 A1 · Owner: Phillips, David R. · Inventors: Phillips, David R.; Law, Deborah Ann
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to mammals into which foreign DNA has been introduced or in which various modifications or substitutions have been made to an integrin .beta. subunit, thereby generating transgenic or geneticallyengineered non-human mammals. In particular the present invention provides a , transgenic mammal in which the endogenous GP IIIa gene has been replaced with an altered or mutant GP IIIa gene in which one or all of the phosphorylatable cytoplasmic tyrosine residues have been replaced with non-tyrosine residues such as phenylalanine. Since the platelets in the blood of the resultant transgenic mammals expressing the altered or mutant GP IIIa cannot undergo tyrosine …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 15, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 15, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 15, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.